Status
Conditions
About
The goal of this observational study is to learn about the causes, severity, and long-term effects of respiratory tract infections (RTIs) in young children from birth to five years of age in Colombia and Panamá. The main questions it aims to answer are:
How often do respiratory infections occur in children under two years old, and which viruses or bacteria cause them? Why do some children develop more severe infections than others? Do early infections or vaccinations change how the immune system responds to future illnesses? How do viruses and bacteria interact in the respiratory tract to influence disease severity and long-term respiratory health? Researchers will follow newborns from birth until age five to understand how respiratory infections develop and affect children's health over time. Participants will not receive any experimental treatment.
Families who join the study will:
Be contacted twice a week through a phone app or phone calls to check for symptoms of respiratory infection.
Attend in-person visits if their child becomes ill and every six months for routine follow-up.
Provide nasal and blood samples during illness episodes so researchers can identify the viruses or bacteria causing infection and study how the immune system responds.
This study began in May 2024 and is being conducted in Cali, Colombia, and Panamá City, Panamá. The research team plans to continue to include participants and continue active follow-up until the children reach five years of age.
The information collected will help scientists and health professionals understand how different pathogens cause respiratory infections, what factors increase the risk of severe illness, and how early infections may influence long-term lung health. The study's findings will support future efforts to prevent and treat respiratory diseases in young children.
Full description
Respiratory tract infections (RTIs) remain one of the most common causes of illness and death in young children, despite advances in vaccination and health programs. In children under five years of age, RTIs cause significant morbidity, social costs, and long-term health consequences. The clinical spectrum of RTI ranges from mild upper infections to severe lower respiratory tract infections (LRTIs) such as bronchiolitis and pneumonia. Viruses are the leading cause, especially in the first two years of life. However, in Latin America, there is limited information about how often RTIs occur, what viruses or bacteria are responsible, and how severe these infections are in community settings. Most existing data come from hospitalized cases, which underestimate the real disease burden.
To address this gap, researchers launched the MINERVAL study, a multicenter, prospective birth cohort conducted in Cali, Colombia, and Panamá City, Panamá. The study began in May 2024 and follows children from birth to five years of age to better understand the epidemiology, etiology, and consequences of RTIs. A total of 436 newborns have been enrolled as of February 2025. This population-based cohort is followed by active surveillance twice a week using a phone app or calls, with in-person visits during RTI episodes and routine visits every six months in the first two years of life. From ages two to five, children continue follow-up every six months to assess long-term outcomes.
The study has four main objectives: (1) to determine the incidence, etiology, and seasonality of RTIs in children aged 0-2 years; (2) to assess the pathogen-specific burden of infections caused by viruses such as RSV, hMPV, influenza, SARS-CoV-2, and others across outpatient and inpatient settings; (3) to evaluate long-term respiratory sequelae of LRTIs during early life and their association with chronic respiratory illness by age five; and (4) to analyze viral-bacterial interactions, focusing on how pneumococcal bacterial loads and immune responses influence disease progression.
Preliminary data from 436 participants show 222 RTI episodes, including 42 LRTIs. The cumulative incidence of RTI was 40% at 100 days and 64.8% at 250 days. For LRTIs, incidence was 8.9% at 100 days and 12.2% at 250 days. Among LRTIs, 82.9% were mild, 14.6% moderate, and 2.4% severe. More than half of LRTI episodes required hospitalization, and 14.3% required intensive care. Samples have been collected from 91% of episodes for laboratory analysis.
These findings confirm the feasibility of long-term active surveillance in this cohort and the high frequency of early-life respiratory infections. The continued study will provide critical insights into the incidence, mechanisms, and long-term health consequences of RTIs in Latin American children, supporting the development of new preventive and therapeutic strategies.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
1,088 participants in 1 patient group
Loading...
Central trial contact
Eduardo Lopez-Medina, MD, MSc; Rodrigo DeAntonio, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal